James Carruth, MD
Pulmonary Disease · Paris, TNNPI 1659360733
Payments from drug & device makers
Across 299 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$935
- GSK$672
- Amgen$477
- Mylan Specialty L.p.$322
- Grifols USA, LLC$268
- Boehringer Ingelheim$244
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,65899%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $935 |
| GSK | 62 | $672 |
| Amgen | 29 | $477 |
| Mylan Specialty L.p. | 21 | $322 |
| Grifols USA, LLC | 18 | $268 |
| Boehringer Ingelheim | 15 | $244 |
| Genentech USA, Inc. | 16 | $220 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $203 |
| Regeneron Healthcare Solutions, Inc. | 10 | $165 |
| Insmed, Inc. | 8 | $163 |
| Verona Pharma, Inc. | 8 | $158 |
| Mallinckrodt Enterprises LLC | 9 | $145 |
| Mallinckrodt Hospital Products Inc. | 6 | $112 |
| ANI Pharmaceuticals, Inc. | 4 | $81 |
| Viatris Specialty LLC | 4 | $69 |
| Sanofi | 4 | $66 |
| Advanced Respiratory, Inc | 4 | $59 |
| Vapotherm Inc | 3 | $55 |
| Electromed, Inc. | 4 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Philips North America LLC | 2 | $38 |
| Baxter Healthcare | 2 | $34 |
| United Therapeutics Corporation | 2 | $27 |
| Novartis | 2 | $26 |
| Johnson & Johnson | 1 | $19 |
| CSL Behring | 1 | $17 |
| AbbVie | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Pulmonx Corporation | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,709 in reported general payments places this provider in the 55th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 383 | $290,095 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $165,938 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 94 | $84,415 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 140 | $71,612 |
| TezspireTezepelumab-Ekko | 11 | $46,929 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 60 | $34,315 |
| Spiriva HandihalerTiotropium Bromide | 32 | $20,784 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $20,705 |
| Theophylline ErTheophylline Anhydrous | 314 | $19,803 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $18,312 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 683 | $17,062 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 27 | $13,492 |
| Spiriva RespimatTiotropium Bromide | 22 | $13,240 |
| Serevent DiskusSalmeterol Xinafoate | 29 | $12,979 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $10,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $672 | $380,019566 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $203 | $165,93812 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $935 | $165,541199 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat, Striverdi Respimat | $244 | $60,094112 claims |
| MerckDulera | $12 | $8,25617 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $39 | $5,95244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Paris
- Fabien MaldonadoNashville$2.5M
- Aaron MilstoneFranklin$2.4M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Clyde SouthwellHendersonville$801K
- Krishnendu BhadraChattanooga$631K
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.